Dependence on HIFU adoption
The growth strategy relies on hospitals and clinics adopting Focal One and treatment workflows.
- Scope
- U.S. and Europe commercialization
- Materiality
- high
Edap TMS SA
EDAP TMS SA develops and commercializes minimally invasive medical systems, centered on its Focal One robotic high-intensity focused ultrasound (HIFU) platform for prostate care. The company also has legacy lithotripsy (ESWL) and medical device distribution activities, with operations and sales across the United States, Europe, and other international markets.
−30,2 %
42,5 %
−41,5 %
+10,0 %
1.54
1.19
| % | |
|---|---|
| HIFU systems and treatment revenue | 65% Robotic HIFU systems, disposables, RPP arrangements, leases, and related services. |
| HIFU maintenance and installed-base services | 7% Maintenance contracts and support services for installed Focal One systems. |
| ESWL products and services | 8% Legacy lithotripsy consumables, spare parts, repair services, and residual system activity. |
| Distribution services | 20% Third-party medical device distribution and related consumables, leasing, and services. |
EDAP sells primarily to hospitals, urology centers, and other healthcare providers that treat prostate and stone...
- Hospitals and academic medical centersprimary
Buy Focal One systems and related services to add minimally invasive prostate treatment capability.
- Urology clinics and treatment centersprimary
Use RPP and lease arrangements to access HIFU technology with lower upfront capital needs.
- Installed-base ESWL customerssecondary
Purchase consumables, spare parts, and repairs for existing lithotripsy systems.
- Medical device distribution customerssecondary
Buy third-party devices and related consumables through the distribution channel.
EDAP has a multinational footprint, with meaningful activity in the United States and Europe and additional sales in...
- •United States is a key market for Focal One system placements
- •Europe uses an RPP model for HIFU revenue generation
- •Other jurisdictions support additional system sales and services
- •Installed-base geography drives recurring maintenance and consumables demand
- •Regional commercial models affect revenue timing and predictability
EDAP’s strategy is centered on expanding its proprietary HIFU franchise and reducing reliance on legacy ESWL and...
01
Expand HIFU commercializationshort-term
HIFU is the core proprietary platform and the main driver of future growth.
02
Build recurring revenue streamsmedium-term
RPP, leases, disposables, and maintenance reduce dependence on one-time equipment sales.
03
Reduce reliance on legacy businessesmedium-term
ESWL and distribution are lower-priority activities and less central to the company’s platform strategy.
EDAP depends on adoption of a specialized medical technology, so demand can be affected by hospital capital budgets,...
Financing and dilution risk
Commercialization and R&D needs may require additional capital if operating cash generation is insufficient.
- Scope
- Corporate funding
- Materiality
- high
Revenue timing from leases and RPP contracts
Operating leases and revenue-per-procedure models spread revenue over time and can create quarter-to-quarter volatility.
- Scope
- HIFU division
- Materiality
- high
Legacy business decline
ESWL system sales have ended and distribution agreements have been terminated, reducing legacy revenue streams.
- Scope
- ESWL and Distribution divisions
- Materiality
- medium
Foreign exchange and tariff exposure
The company operates internationally and has disclosed tariff impact and euro-dollar sensitivity.
- Scope
- Europe and cross-border supply chain
- Materiality
- medium
Revenue recognition by business model
Can shift revenue between quarters and change gross margin mix
Fair value of warrants and debt-related instruments
Can create volatility in non-operating income or expense
Foreign currency translation and transaction effects
Can materially affect reported earnings and cash balances
Lease accounting and installed-base arrangements
Influences balance sheet structure and recurring revenue profile
: 16/06/2026